Asia-Pacific active pharmaceutical ingredient market is projected to boom in the upcoming five years while exhibiting an impressive CAGR. In the last five years, from 2017 to 2021, the market has experienced quite a growth that was counted in millions of sales. It is anticipated to project its growth in the forecast period, 2023-2027, on account of rapidly increasing research and advancement in the active pharmaceutical ingredients to enhance the quality and efficiency of the drugs they are a part of.

Moreover, an abundance of the market players in the region is also one of the major factors responsible for the growth of the Asia Pacific active pharmaceutical ingredient market in the upcoming five years. Also, favorable government regulations for active pharmaceutical ingredient production, along with the changes in geopolitical changes, are supporting the growth of the Asia Pacific active pharmaceutical ingredient market in the forecast years until 2027.

Furthermore, the rising geriatric population of the region is influencing the growth of the Asia Pacific active pharmaceutical ingredient market in the next five years. Any substance or combination of substances used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings is the textbook definition of active pharmaceutical ingredient (API).

The Asia Pacific active pharmaceutical ingredient market is segmented by the method of synthesis, source, therapeutic application, molecule type, potency, drug type, competitional landscape, and regional distribution. Based on the method of synthesis, the market is further bifurcated into biological and synthetic methods of synthesis. Synthetic methods of synthesis are anticipated to hold the larger revenue shares of the market in the upcoming five years on account of the availability of raw materials and easier protocols for the synthesis of active pharmaceutical ingredients. Also, the increasing presence of the soon-to-be off-patent molecules is expected to further boost the market growth in the next five years of forecast.

Holding the largest shares of the Asia Pacific active pharmaceutical ingredient market revenue, market players like Cipla Limited, Pfizer, Inc., Dr. Reddy's Laboratories Ltd., Symbiotica Speciality Ingredients Sdn. Bhd., ScinoPharm Taiwan Ltd, Zhejiang Hisun Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., AbbVie Inc., AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Lupin Limited, Nanjing Pharmaceutical Factory Co. Ltd., among others are actively involved with the research and development process of the Active Pharmaceutical Ingredients in the region.

Countries like India, China, Japan have dedicated research labs for advanced products development and consistent product modifications. China is the largest market, followed by India, Japan, and Taiwan. Research and technological advancement for the high potency active pharmaceutical ingredient would be the best strategy for the new market players entering the market. Other strategic recommendations can be collaboration and inter-dependency with the existent market giants. The market is well developed, and the presence of multiple market players in the major economies of the region is actively influencing the market growth.  

Objective of the Study:

  • To analyze and forecast the market size of Asia-Pacific active pharmaceutical ingredient market from 2017 to 2020.
  • To estimate and forecast the market size of Asia-Pacific active pharmaceutical ingredient market from 2021 to 2027 and growth rate until 2027. 
  • To classify and forecast Asia-Pacific active pharmaceutical ingredient market based on method of synthesis, source, therapeutic application, molecule type, potency, drug type, competitional landscape, and country distributions.
  • To identify dominant region or segment in the Asia-Pacific active pharmaceutical ingredient market.
  • To identify drivers and challenges for Asia-Pacific active pharmaceutical ingredient market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Asia-Pacific active pharmaceutical ingredient market.
  • To identify and analyze the profile of leading players operating in Asia-Pacific active pharmaceutical ingredient market.
  • To identify key sustainable strategies adopted by market players in Asia-Pacific active pharmaceutical ingredient market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of Asia-Pacific active pharmaceutical ingredient market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers, end users, and other stakeholders
  • Distributers and suppliers and other stakeholders
  • Organizations, forums, and alliances related to active pharmaceutical ingredients.
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Attribute

Details

Base Year

2021

Historic Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Method of Synthesis

·         Source

·         Therapeutic Application

·         Molecule Type

·         Potency

·         Drug Type

Country scope

China; India; Japan; South Korea; Taiwan; Vietnam; Philippines; Indonesia; Malaysia; Australia

Key companies profiled

Cipla Limited, Pfizer, Inc., Dr. Reddy's Laboratories Ltd., Symbiotica Speciality Ingredients Sdn. Bhd., ScinoPharm Taiwan Ltd, Zhejiang Hisun Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., AbbVie Inc., AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Lupin Limited, Nanjing Pharmaceutical Factory Co. Ltd.

Customization scope

10% free report customization with purchase. Addition or alteration to country, & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, Asia-Pacific active pharmaceutical ingredient market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Asia-Pacific Active Pharmaceutical Ingredient Market, By Method of Synthesis:
    • Biological
    • Synthetic
  • Asia-Pacific Active Pharmaceutical Ingredient Market, By Source:

o   Contact Manufacturing Organizations

o   In-House Manufacturing

  • Asia-Pacific Active Pharmaceutical Ingredient Market, By Therapeutic Application:

o   Cardiovascular Diseases

o   Anti-diabetic Drugs

o   Oncology Drugs

o   Neurological Disorders

o   Musculoskeletal Disorders

o   Others

  • Asia-Pacific Active Pharmaceutical Ingredient Market, By Molecule Type:

o   Small

o   Large

  • Asia-Pacific Active Pharmaceutical Ingredient Market, By Potency:
    • Low
    • High
  • Asia-Pacific Active Pharmaceutical Ingredient Market, By Drug Type:
    • Innovator
    • Generics
  • Asia-Pacific Active Pharmaceutical Ingredient Market, By Country:
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Vietnam
    • Philippines
    • Indonesia
    • Malaysia
    • Australia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Asia-Pacific active pharmaceutical ingredient market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Asia-Pacific Active Pharmaceutical Ingredient Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Asia Pacific Active Pharmaceutical Ingredients Market

4.    Executive Summary

5.    Voice of Customer

6.    Asia Pacific Active Pharmaceutical Ingredients Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Method of Synthesis (Biological v/s Synthetic)

6.2.2.     By Source (Contact Manufacturing Organizations v/s In-House Manufacturing)

6.2.3.     By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others)

6.2.4.     By Molecule Type (Small v/s Large)

6.2.5.     By Potency (Low v/s High)

6.2.6.     By Drug Type (Innovator v/s Generics)

6.2.7.     By Region

6.2.8.     By Company (2021)

6.3.  Product Market Map

7.    China Active Pharmaceutical Ingredients Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Method of Synthesis

7.2.2.     By Source

7.2.3.     By Therapeutic Application

7.2.4.     By Molecule Type

7.2.5.     By Potency

7.2.6.     By Drug Type

8.    India Active Pharmaceutical Ingredients Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Method of Synthesis

8.2.2.     By Source

8.2.3.     By Therapeutic Application

8.2.4.     By Molecule Type

8.2.5.     By Potency

8.2.6.     By Drug Type

9.    Japan Active Pharmaceutical Ingredients Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Method of Synthesis

9.2.2.     By Source

9.2.3.     By Therapeutic Application

9.2.4.     By Molecule Type

9.2.5.     By Potency

9.2.6.     By Drug Type

10.  South Korea Active Pharmaceutical Ingredients Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Method of Synthesis

10.2.2.  By Source

10.2.3.  By Therapeutic Application

10.2.4.  By Molecule Type

10.2.5.  By Potency

10.2.6.  By Drug Type

11.  Taiwan Active Pharmaceutical Ingredients Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Method of Synthesis

11.2.2.  By Source

11.2.3.  By Therapeutic Application

11.2.4.  By Molecule Type

11.2.5.  By Potency

11.2.6.  By Drug Type

12.  Vietnam Active Pharmaceutical Ingredients Market Outlook

12.1.              Market Size & Forecast

12.1.1.  By Value

12.2.              Market Share & Forecast

12.2.1.  By Method of Synthesis

12.2.2.  By Source

12.2.3.  By Therapeutic Application

12.2.4.  By Molecule Type

12.2.5.  By Potency

12.2.6.  By Drug Type

13.  Philippines Active Pharmaceutical Ingredients Market Outlook

13.1.              Market Size & Forecast

13.1.1.  By Value

13.2.              Market Share & Forecast

13.2.1.  By Method of Synthesis

13.2.2.  By Source

13.2.3.  By Therapeutic Application

13.2.4.  By Molecule Type

13.2.5.  By Potency

13.2.6.  By Drug Type

14.  Indonesia Active Pharmaceutical Ingredients Market Outlook

14.1.              Market Size & Forecast

14.1.1.  By Value

14.2.              Market Share & Forecast

14.2.1.  By Method of Synthesis

14.2.2.  By Source

14.2.3.  By Therapeutic Application

14.2.4.  By Molecule Type

14.2.5.  By Potency

14.2.6.  By Drug Type

15.  Malaysia Active Pharmaceutical Ingredients Market Outlook

15.1.              Market Size & Forecast

15.1.1.  By Value

15.2.              Market Share & Forecast

15.2.1.  By Method of Synthesis

15.2.2.  By Source

15.2.3.  By Therapeutic Application

15.2.4.  By Molecule Type

15.2.5.  By Potency

15.2.6.  By Drug Type

16.  Australia Active Pharmaceutical Ingredients Market Outlook

16.1.              Market Size & Forecast

16.1.1.  By Value

16.2.              Market Share & Forecast

16.2.1.  By Method of Synthesis

16.2.2.  By Source

16.2.3.  By Therapeutic Application

16.2.4.  By Molecule Type

16.2.5.  By Potency

16.2.6.  By Drug Type

17.  Market Dynamics

17.1.              Drivers

17.2.              Challenges

18.  Market Trends & Developments

19.  Competitive Landscape

19.1.              Competition Outlook

19.2.              Company Profiles (Includes SWOT Analysis)

19.2.1.  Cipla Limited

19.2.2.  Pfizer, Inc.

19.2.3.  Dr. Reddy's Laboratories Ltd.

19.2.4.  Symbiotica Speciality Ingredients Sdn. Bhd.

19.2.5.  ScinoPharm Taiwan Ltd

19.2.6.  Zhejiang Hisun Pharmaceutical Co. Ltd.

19.2.7.  Aurobindo Pharma Ltd.

19.2.8.  Sun Pharmaceutical Industries Ltd.

19.2.9.  Teva Pharmaceutical Industries Ltd.

19.2.10.                AbbVie Inc.

19.2.11.                AstraZeneca plc

19.2.12.                GlaxoSmithKline plc

19.2.13.                Sanofi S.A.

19.2.14.                Lupin Limited

19.2.15.                Nanjing Pharmaceutical Factory Co. Ltd.

20.  Strategic Recommendations

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com